Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • OtherClosed to enrollment Location: Australia

    Clinical and psychosocial changes over late childhood and adolescence and early life determinants of long term clinical outcomes in cystic fibrosis Study , protocol number ACTRN12613000778785

    The purpose of the study is to further improve outcomes in CF by developing a better understanding of the reasons for the decline in health status and lung function during adolescence, which is one of the key challenges facing clinicians. We hope to do this by looking at such things such as the 1) pathology involved in CF lung disease, 2) long term risk of emerging organisms, 3) potential effects of early therapeutic interventions, such as P. aeruginosa eradication, 4) metagenomic profile identifying bacteria in respiratory samples, 5) psychosocial factors, and 6) relationship between early life events and outcomes between 9-17 years of age.

    • Age:

      9 - 15 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherRecruiting Location: Australia - NSW, QLD, SA, VIC, WA

    CF-IDEA (Cystic Fibrosis - Insulin Deficiency, Early Action): randomised controlled trial of once-daily insulin determir inpatients with cystic fibrosis and early insulin deficiency , protocol number ACTRN12611000068965

    Cystic fibrosis (CF) is the most common life-threatening genetic condition affecting Australian children. As well as repeated lung infections, children with CF develop insulin deficiency and eventually diabetes. The CF-IDEA trial will determine whether starting insulin treatment before the onset of diabetes (earlier than current practice) will improve the health of children with CF by improving body weight and lung function.

    • Age:

      5 - 19 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: NSW - Australia

    A Phase 3 multi-centre randomised placebo-controlled study of azithromycin in the primary prevention of radiologically-defined bronchiectasis in infants with cystic fibrosis (COMBATCF). , protocol number NCT01270074 ACTRN12610001072000

    The general aim of this project is to conduct a randomized double-blind, placebo-controlled clinical trial of azithromycin to determine whether treatment from infancy is safe and will prevent the onset of bronchiectasis. One hundred and thirty infants will be recruited from CF clinics in Australia and New Zealand and treated from 3 months to three years of age. The primary outcome will be the proportion with radiologically-defined bronchiectasis at 3 years of age. Safety and mechanistic evaluations will also be undertaken.

    • Age:

      6 Weeks to 6 Months

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: NSW - Australia

    Randomised controlled trial to be determine whether once-daily insulin detemir slows decline in weight and lung functions in patients with cystic fibrosis and early insulin deficiency. , protocol number NCT01100892 ACTRN13611000068965

    Cystic fibrosis (CF) is the most common life-threatening genetic condition affecting Australian children. As well as repeated lung infections, children with CF develop insulin deficiency and eventually diabetes. The CF-IDEA trial (Cystic Fibrosis - Insulin Deficiency, Early Action) will determine whether starting insulin treatment before the onset of diabetes (earlier than current practice) will improve the health of children with CF by improving body weight and lung function.

    • Age:

      5 Years to 19 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Anti-InfectiveActive, not recruiting Location: Australia

    A randomised, prospective, double-blind trial of long-term daily versus weekly azithromycin to determine the effect of dose on disease parameters in cystic fibrosis. , protocol number ACTRN12605000162617

    A randomised, prospective, double-blind trial of long-term daily versus weekly azithromycin to determine the effect of dose on disease parameters in cystic fibrosis.

    • Age:

      > 6 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      with 10% of average for last 6 months

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Australia

    Fungal exposure and fungal-specific IgE in subjects with cystic fibrosis (Australian Cystic Fibrosis Research Trust 2004/052) , protocol number ACTRN12605000156684

    Fungal exposure and fungal-specific IgE in subjects with cystic fibrosis (Australian Cystic Fibrosis Research Trust 2004/052)

    • Age:

      Not Specified

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Nutritional-GIActive, not recruiting Location: Australia

    Prevalence and predictors of malnutrition and decreased bone density in cystic fibrosis. , protocol number ACTRN12605000426684

    Prevalence and predictors of malnutrition and decreased bone density in cystic fibrosis.

    • Age:

      >18 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Nutritional-GIRecruiting Location: Australia

    Gastric emptying and malnutrition in adults with cystic fibrosis. , protocol number ACTRN12605000427673

    Gastric emptying and malnutrition in adults with cystic fibrosis.

    • Age:

      >18 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Australia

    Effect of Positive Expiratory Pressure (PEP) on the duration of the exacerbation-free period in people with cystic fibrosis (CF). , protocol number ACTRN12605000348651

    Effect of Positive Expiratory Pressure (PEP) on the duration of the exacerbation-free period in people with cystic fibrosis (CF).

    • Age:

      Not Specified

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      FEV1 within 15% of their best recorded value as an outpatient for the preceding six months

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherNot yet recruiting Location: Australia

    Phase 3, placebo-controlled, parallel group randomised trial of the effect of nebulised hypertonic saline on the length of stay of people hospitalised with acute exacerbations of cystic fibrosis lung disease. , protocol number ACTRN12605000780651

    Phase 3, placebo-controlled, parallel group randomised trial of the effect of nebulised hypertonic saline on the length of stay of people hospitalised with acute exacerbations of cystic fibrosis lung disease.

    • Age:

      >17 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Displaying results 21-30 (of 193)
     |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|